Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

NCT03980925 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Neuroendocrine Neoplasm
Gastroenteropancreatic Neuroendocrine Tumor

Interventions

DRUG: Nivolumab
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Grupo Espanol de Tumores Neuroendocrinos